AstraZeneca’s COVID-19 vaccine has just undergone a phase III trial in the U.S., demonstrating 79% efficacy at preventing symptomatic COVID-19 and 11% efficacy at preventing severe disease and hospitalization.
AstraZeneca vaccine shows 79% efficacy in phase III trial
